PortfoliosLab logoPortfoliosLab logo
SNY vs. NVS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SNY vs. NVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sanofi (SNY) and Novartis AG (NVS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SNY achieves a -6.78% return, which is significantly lower than NVS's 7.24% return. Over the past 10 years, SNY has underperformed NVS with an annualized return of 4.63%, while NVS has yielded a comparatively higher 9.83% annualized return.


SNY

1D
-0.37%
1M
-1.96%
YTD
-6.78%
6M
-9.38%
1Y
-8.16%
3Y*
-1.21%
5Y*
0.44%
10Y*
4.63%

NVS

1D
-1.51%
1M
-2.11%
YTD
7.24%
6M
11.77%
1Y
26.69%
3Y*
17.18%
5Y*
14.14%
10Y*
9.83%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SNY vs. NVS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SNY
Sanofi
-6.78%4.93%1.09%6.55%0.57%7.00%0.39%20.47%6.06%9.96%
NVS
Novartis AG
7.24%46.95%0.02%16.14%8.06%-3.65%3.34%13.92%5.95%19.42%

Correlation

The correlation between SNY and NVS is 0.53, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.53

Correlation (3Y)
Calculated over the trailing 3-year period

0.50

Correlation (5Y)
Calculated over the trailing 5-year period

0.53

Correlation (10Y)
Calculated over the trailing 10-year period

0.54

Correlation (All Time)
Calculated using the full available price history since Jul 2, 2002

0.55

The correlation between SNY and NVS has been stable across timeframes, ranging from 0.50 to 0.55 - a consistent structural relationship.

Fundamentals

Market Cap

SNY:

$103.08B

NVS:

$274.91B

EPS

SNY:

$3.09

NVS:

$6.99

PE Ratio

SNY:

13.86

NVS:

20.53

PS Ratio

SNY:

2.21

NVS:

4.96

PB Ratio

SNY:

1.42

NVS:

7.14

Total Revenue (TTM)

SNY:

$47.35B

NVS:

$56.05B

Gross Profit (TTM)

SNY:

$34.18B

NVS:

$42.19B

EBITDA (TTM)

SNY:

$12.63B

NVS:

$22.40B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SNY vs. NVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNY
SNY Risk / Return Rank: 2323
Overall Rank
SNY Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
SNY Sortino Ratio Rank: 2424
Sortino Ratio Rank
SNY Omega Ratio Rank: 2323
Omega Ratio Rank
SNY Calmar Ratio Rank: 2323
Calmar Ratio Rank
SNY Martin Ratio Rank: 1919
Martin Ratio Rank

NVS
NVS Risk / Return Rank: 7575
Overall Rank
NVS Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
NVS Sortino Ratio Rank: 7373
Sortino Ratio Rank
NVS Omega Ratio Rank: 7070
Omega Ratio Rank
NVS Calmar Ratio Rank: 7676
Calmar Ratio Rank
NVS Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNY vs. NVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SNYNVSDifference

Sharpe ratio

Return per unit of total volatility

-0.33

1.32

-1.65

Sortino ratio

Return per unit of downside risk

-0.28

1.88

-2.17

Omega ratio

Gain probability vs. loss probability

0.96

1.23

-0.27

Calmar ratio

Return relative to maximum drawdown

-0.51

2.19

-2.70

Martin ratio

Return relative to average drawdown

-1.01

5.58

-6.59

SNY vs. NVS - Sharpe Ratio Comparison

The current SNY Sharpe Ratio is -0.33, which is lower than the NVS Sharpe Ratio of 1.32. The chart below compares the historical Sharpe Ratios of SNY and NVS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SNYNVSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.33

1.32

-1.65

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.02

0.76

-0.74

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.20

0.50

-0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.20

0.42

-0.21

Drawdowns

SNY vs. NVS - Drawdown Comparison

The maximum SNY drawdown since its inception was -46.46%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for SNY and NVS.


Loading charts...

Drawdown Indicators


SNYNVSDifference

Max Drawdown

Largest peak-to-trough decline

-46.46%

-42.10%

-4.36%

Max Drawdown (1Y)

Largest decline over 1 year

-16.70%

-12.65%

-4.05%

Max Drawdown (3Y)

Largest decline over 3 years

-23.37%

-19.95%

-3.42%

Max Drawdown (5Y)

Largest decline over 5 years

-33.52%

-20.42%

-13.10%

Max Drawdown (10Y)

Largest decline over 10 years

-33.52%

-26.03%

-7.49%

Current Drawdown

Current decline from peak

-20.60%

-12.32%

-8.28%

Average Drawdown

Average peak-to-trough decline

-12.19%

-10.93%

-1.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.39%

4.97%

+3.42%

Volatility

SNY vs. NVS - Volatility Comparison

The current volatility for Sanofi (SNY) is 5.39%, while Novartis AG (NVS) has a volatility of 5.77%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SNYNVSDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.39%

5.77%

-0.38%

Volatility (6M)

Calculated over the trailing 6-month period

14.94%

14.30%

+0.64%

Volatility (1Y)

Calculated over the trailing 1-year period

24.93%

20.29%

+4.64%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.68%

18.78%

+5.90%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.42%

19.59%

+3.83%

Dividends

SNY vs. NVS - Dividend Comparison

SNY's dividend yield for the trailing twelve months is around 5.66%, more than NVS's 3.33% yield.


PositionTTM20252024202320222021202020192018201720162015
NVS
Novartis AG
3.33%2.90%3.84%3.44%3.70%3.86%3.22%3.03%3.47%3.24%3.73%3.10%
SNY
Sanofi
5.66%4.56%4.22%3.83%4.32%3.80%3.61%3.47%4.29%3.82%4.11%3.77%

Financials

SNY vs. NVS - Financials Comparison

This section allows you to compare key financial metrics between Sanofi and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


8.00B10.00B12.00B14.00B20222023202420252026
11.24B
13.52B
(SNY) Total Revenue
(NVS) Total Revenue
Values in USD except per share items

SNY vs. NVS - Profitability Comparison

The chart below illustrates the profitability comparison between Sanofi and Novartis AG over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

66.0%68.0%70.0%72.0%74.0%76.0%78.0%20222023202420252026
72.1%
74.4%
Portfolio components
SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.


Frequently Asked Questions


SNY and NVS have a correlation of 0.53, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVS has higher volatility (5.77%) compared to SNY (5.39%). In terms of maximum drawdown, SNY dropped -46.46% vs NVS's -42.10%.

NVS currently has the higher Sharpe Ratio (1.32 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SNY and NVS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer